Pie Medical Imaging announces the results of the LIPSIA-STRATEGY trial, showcasing CAAS vFFR's effectiveness in coronary revascularization compared to traditional methods.

The LIPSIA-STRATEGY trial marks a significant advancement in revascularization techniques, showing that CAAS vFFR guidance offers similar outcomes to pressure wire methods.

The LIPSIA-STRATEGY trial demonstrates that revascularization guided by CAAS vFFR is as effective as traditional methods, providing a less invasive option for patients.

The LIPSIA-STRATEGY trial confirms that angiography-based CAAS vFFR guided revascularization is as effective as wire-based methods, enhancing patient safety and procedure efficiency.

The FAST III trial reveals that the CAAS vFFR, a non-invasive method for assessing coronary lesions, matches the effectiveness of invasive pressure wire techniques, promising patient benefits.

The FAST III study provides significant evidence that CAAS vFFR offers comparable results to traditional wire-based FFR, enhancing cardiac treatment options.

The recent FAST III trial demonstrates that CAAS vFFR provides non-inferior results compared to traditional invasive FFR, offering a safer, minimally invasive alternative for patients.

Discover the groundbreaking results of the FAST III trial comparing CAAS vFFR to traditional methods, promising safer and less invasive cardiac assessments.

The FAST III study reveals that the CAAS vFFR method provides comparable results to the invasive pressure wire FFR for guiding coronary revascularization. This finding has significant implications for patient treatment.